ABSTRACT
Renal involvement in patients with Systemic Lupus Erythematosus is frequent causing considerable morbidity and mortality. Conventional therapy consists of immunosuppressive medications administered in two stages, induction followed by a maintenance phase. Different drugs result in similar outcomes although with adverse events and relapses. Here we present a brief review of the published literature regarding new approaches in therapy with emphasis on biological treatment and lupus nephritis...
La afectación renal en pacientes con Lupus Eritematoso Sistémico es frecuente, causando un aumento tanto de la morbilidad como la mortalidad. El tratamiento convencional incluye inmunosupresores en una fase de inducción y otra de mantención, con una eficacia similar entre ellos, sin embargo pueden presentar efectos adversos graves y recaídas de la enfermedad. A continuación se presenta una breve revisión de la literatura publicada respecto a los nuevos tratamientos biológicos y nefritis lúpica...
Subject(s)
Humans , Antibodies, Monoclonal/therapeutic use , Biological Therapy , Lupus Nephritis/drug therapyABSTRACT
Libman-Sacks endocarditis is a non-infectious valvular damage associated with autoimmune disorders such as Systemic Lupus Erythematosus and Antiphospholipid Syndrome. We report a 17-year-old female consulting in the emergency room due to a right hemiparesis and aphasia. A magnetic resonance imaging showed multiple infarctions in the territory of the left middle cerebral artery, presumably of embolic origin. A trans-esophageal echocardiogram showed a vegetation in the mitral valve. Blood cultures were negative. Antinuclear antibodies and serological tests for antiphospholipid syndrome were positive. Oral anticoagulation was started and the patient was discharged. After six months of follow up, antiphospholipid antibodies are still positive.